BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10452630)

  • 1. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.
    Bessesen M; Ives D; Condreay L; Lawrence S; Sherman KE
    Clin Infect Dis; 1999 May; 28(5):1032-5. PubMed ID: 10452630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study.
    Bellini C; Keiser O; Chave JP; Evison J; Fehr J; Kaiser L; Weber R; Vernazza P; Bernasconi E; Telenti A; Cavassini M;
    HIV Med; 2009 Jan; 10(1):12-8. PubMed ID: 18795964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient.
    Neau D; Schvoerer E; Robert D; Dubois F; Dutronc H; Fleury HJ; Ragnaud JM
    J Infect; 2000 Sep; 41(2):192-4. PubMed ID: 11023772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
    Hoff J; Bani-Sadr F; Gassin M; Raffi F
    Clin Infect Dis; 2001 Mar; 32(6):963-9. PubMed ID: 11247719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis B in HIV co-infected patients.
    Guan R
    Med J Malaysia; 2005 Jul; 60 Suppl B():52-6. PubMed ID: 16108174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
    Ristig MB; Crippin J; Aberg JA; Powderly WG; Lisker-Melman M; Kessels L; Tebas P
    J Infect Dis; 2002 Dec; 186(12):1844-7. PubMed ID: 12447773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
    Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
    Benhamou Y; Bochet M; Thibault V; Di Martino V; Caumes E; Bricaire F; Opolon P; Katlama C; Poynard T
    Hepatology; 1999 Nov; 30(5):1302-6. PubMed ID: 10534354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
    J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
    Rouet F; Chaix ML; Inwoley A; Anaky MF; Fassinou P; Kpozehouen A; Rouzioux C; Blanche S; Msellati P;
    Clin Infect Dis; 2008 Feb; 46(3):361-6. PubMed ID: 18171303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
    J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART.
    Drake A; Mijch A; Sasadeusz J
    Clin Infect Dis; 2004 Jul; 39(1):129-32. PubMed ID: 15206064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.
    Matthews GV; Manzini P; Hu Z; Khabo P; Maja P; Matchaba G; Sangweni P; Metcalf J; Pool N; Orsega S; Emery S;
    AIDS; 2011 Sep; 25(14):1727-35. PubMed ID: 21716078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
    Treviño A; Soriano V; Madejon A; Rodriguez C; Barros C; Botecchia M; Tuma P; Del Romero J; de Mendoza C
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1273-6. PubMed ID: 20001517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.